Home Angiogenesis Bcr-Abl inhibitor - DUB inhibitor - Autophagy inhibitor - Apoptosis related activator Degrasyn (WP1130) For research use only.

Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.

Degrasyn (WP1130) Chemical Structure

Degrasyn (WP1130) Chemical Structure

CAS: 856243-80-6

Selleck's Degrasyn (WP1130) has been cited by 42 publications

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Other Bcr-Abl Products

Related compound libraries

Choose Selective Bcr-Abl Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Mino Cytotoxicity assay 72 hrs Cytotoxicity against human Mino cells after 72 hrs by MTT assay, IC50=0.8μM 24457091
MM1 Antitumor assay 24 to 72 hrs Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay, IC50=1μM 22036213
MM1S Cytotoxicity assay 72 hrs Cytotoxicity against human MM1S cells after 72 hrs by MTT assay, IC50=1.2μM 24457091
U266 Antitumor assay 24 to 72 hrs Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay, IC50=1.3μM 22036213
OCI-My4 Antitumor assay 24 to 72 hrs Antitumor activity against human OCI-My4 cells after 24 to 72 hrs by MTT assay, IC50=1.5μM 22036213
A375 Cytotoxicity assay 72 hrs Cytotoxicity against human A375 cells after 72 hrs by MTT assay, IC50=1.7μM 24457091
K562 Cytotoxicity assay 72 hrs Cytotoxicity against human K562 cells after 72 hrs by MTT assay, IC50=2.4μM 24457091
Z138 Function assay 1 hr Inhibition of UCH-L1 in human Z138 cells after 1 hr by immunoblotting analysis, IC50=3μM 23791076
Z138 Function assay 1 hr Inhibition of USP9x in human Z138 cells after 1 hr by immunoblotting analysis, IC50=3μM 23791076
Z138 Function assay 1 hr Inhibition of USP5 in human Z138 cells after 1 hr by immunoblotting analysis, IC50=3μM 23791076
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells using HA-Ub vinyl-sulfone as substrate at 1.25 to 5 uM after 4 hrs by immunoblotting analysis 24457091
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells at 1.25 to 5 uM incubated for 4 hrs by SDS-PAGE and immunoblotting ChEMBL
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells assessed as reduction in Mcl-1 protein level at 1.25 to 5 uM incubated for 4 hrs by SDS-PAGE and immunoblotting ChEMBL
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells at 1.25 to 5 uM incubated for 4 hrs by immunoblotting analysis ChEMBL
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells assessed as reduction in Mcl1 protein levels at 1.25 to 5 uM incubated for 4 hrs by immunoblotting analysis ChEMBL
Click to View More Cell Line Experimental Data

Biological Activity

Description Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.
Features WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Targets
DUB [1]
(Cell-free assay)		 Bcr-Abl [1]
(Cell-free assay)
1.8 μM
In vitro
In vitro In addition to inducing rapid down-regulation of Bcr/Abl without affecting Bcr or c-Abl, WP1130 also regulates the stability of Jak2 and c-Myc without affecting other kinases (HER1, HER2, c-Kit, FAK, ERK1, ERK2, Akt, Btk, Src and Src-related kinases) or transcription factors (wild-type p53, STAT1, STAT3, STAT5, c-Jun, NF-κB, and Max). Unlike adaphostin and Trisenox, WP1130 induces down-regulation of Bcr/Abl within 60 minutes. WP1130 is more effective in inducing apoptosis of myeloid and lymphoid tumor cells with IC50 of ~0.5-2.5 μM compared with normal CD34+ hematopoietic precursors, dermal fibroblasts, or endothelial cells with IC50 of ~5-10 μM. WP1130 (5 μM) specifically and rapidly down-regulates both wild-type and T315I mutant Bcr/Abl protein without affecting bcr/abl gene expression or engaging the proteasomal degradation pathway in chronic myelogenous leukemia (CML) cells, accompanied by induction of apoptosis. WP1130 is more effective in reducing leukemic cell colony formation compared with normal progenitor cells, and effective against primary leukemic cells harboring the T315I mutation. [1] WP1130 induces rapid proteasomal-dependent degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines, correlated with tumor growth inhibition. [2] Unlike AG490, WP1130 acts as a partly selective deubiquitinase (DUB) inhibitor to induce a rapid and marked accumulation of polyubiquitinated (K48/K63-linked) proteins into juxtanuclear aggresomes without affecting proteasome activity. WP1130 (5 μM) directly inhibits DUB activity of USP9x, USP5, USP14, UCH-L1, and UCH37, but not UCH-L3, resulting in downregulation of antiapoptotic and upregulation of proapoptotic proteins, such as MCL-1 and p53. [3]
Cell Research Cell lines BV173, BV173R, K562, and BaF/3
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 72 hours
Method Cells are treated with increasing concentrations of WP1130 (0.08-10 μM) in 96-well plates. Plates are incubated at 37 °C for 72 hours, after which 20 μL of MTT reagent is added, and the plates are incubated at 37 °C for another 2 hours. Cells are lysed with 100 μL lysis buffer (20% sodium dodecyl sulfate [SDS] in 50% N, N-dimethylformamide adjusted to pH 4.7 with 80% acetic acid and 1 M hydrochloric acid; final concentration of acetic acid is 2.5% and hydrochloric acid is 2.5%) and incubated for 6 hours. The optical density of each sample at 570 nm is determined with a SPECTRA MAX M2 plate reader.
In Vivo
In vivo Administration of WP1130 inhibits the growth of K562 tumors as well as both wildtype Bcr/Abl and T315I mutant Bcr/Abl-expressing BaF/3 cells transplanted into nude mice. [1] Consistent with the down-regulation of c-Myc, WP1130 displays potent inhibitory activity against A375 melanoma tumors established in nude mice. [2]
Animal Research Animal Models Swiss Nu/Nu mice transplanted with K562 tumor cells, BaF/3wt cells, or BaF/3/T315I cells
Dosages ~40 mg/kg every other day
Administration Injected intraperitoneally

Chemical lnformation & Solubility

Molecular Weight 384.27 Formula

C19H18BrN3O
CAS No. 856243-80-6 SDF Download Degrasyn (WP1130) SDF
Smiles CCCC(C1=CC=CC=C1)NC(=O)C(=CC2=NC(=CC=C2)Br)C#N
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 77 mg/mL ( (200.37 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 50 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Degrasyn (WP1130) | Degrasyn (WP1130) supplier | purchase Degrasyn (WP1130) | Degrasyn (WP1130) cost | Degrasyn (WP1130) manufacturer | order Degrasyn (WP1130) | Degrasyn (WP1130) distributor